The FDA expanded eligibility for Moderna's mRESVIA RSV vaccine to include at-risk adults aged 18 and older shortly after approving its updated COVID-19 vaccine. Meanwhile, notable changes in US vaccine advisory panels have emerged as Health Secretary Robert F. Kennedy Jr. replaced the CDC’s immunization committee with new members, some skeptical of vaccines. This transition is taking place as experts voice concerns over the administration's regulatory approach and the potential impact on vaccine confidence and public health policy.